Liapakis Lab
Department of Pharmacology, Faculty of Medicine
University of Crete
Selected Recent Publications
Gkountelias K., Papadokostaki M, Javitch JA, and Liapakis G. (2010). Exploring the binding site crevice of a family B GPCR, the type 1 corticotropin releasing factor receptor. Mol Pharmacol 78:785-793.
http://www.ncbi.nlm.nih.gov/pubmed/20664003
Gkountelias K, Tselios T, Venihaki M, Deraos M, Lazaridis I, Rassouli O, Gravanis A, and Liapakis G (2009). Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin releasing factor receptor revealed residues critical for peptide binding. Mol. Pharmacol, 75:793?800. http://www.ncbi.nlm.nih.gov/pubmed/19124613
Pontikoglou C, Liapakis G, Pyrovolaki K, Papadakis M, Bux J, Eliopoulos GD and Papadaki HA. (2006). Evidence for downregulation of erythropoietin receptor in bone marrow erythroid cells of patients with chronic idiopathic neutropenia. Exp Hematol. 34(10):1312-1322.
http://www.ncbi.nlm.nih.gov/pubmed/16982324
Venihaki M, Sakihara S, Subramanian S, Dikkes P, Weninger SC, Liapakis G, Graf T, Majzoub JA (2004). Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviors. J Neuroendocrinol., 16(5): 411-422. http://www.ncbi.nlm.nih.gov/pubmed/15117334
Liapakis G., Chan W.C., Papadokostaki M. and Javitch J.A. (2004). Synergistic Contributions of the Functional Groups of Epinephrine to its Affinity and Efficacy at the β2 Adrenergic Receptor. Mol Pharmacol, 65(5): 1181-1190.
http://www.ncbi.nlm.nih.gov/pubmed/15102946
Shi L / Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. (2002). [Shi.L. and Liapakis.G. equally contributed to this work]. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem., 277(43): 40989-40996.
http://www.ncbi.nlm.nih.gov/pubmed/12167654
Javitch J.A., Shi L. and Liapakis G (2002). Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors. Methods Enzymol., 343:137-56.
http://www.ncbi.nlm.nih.gov/pubmed/11665562
Ballesteros J.A./ Jensen A.D./ Liapakis G./ Rasmussen S.G.F., Shi L., Gether U., and Javitch J.A. (2001). [Ballesteros, Jensen, Liapakis and Rasmussen equally contributed to this work]. Activation of the b2 adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem., 276(31): 29171-29177.
http://www.ncbi.nlm.nih.gov/pubmed/11375997
Liapakis G., Ballesteros J.A., Papachristou S., Chan W.C., Chen X., and Javitch J.A. (2000) The Forgotten Serine: A critical role for Ser203(5.42) in ligand binding to and activation of the beta2 adrenergic receptor. J Biol Chem., 275(48): 37779-37788.
http://www.ncbi.nlm.nih.gov/pubmed/10964911
Rasmussen S.G.F., Jensen A.D., Liapakis G., Ghanouni P., Javitch J. and Gether U. (1999), Mutation of a highly conserved aspartic acid in the β2 adrenergic receptor: Constitutive activation, structural instability and conformational rearrangement of transmembrane segment 6. Mol. Pharmacol., 56: 175-184.